RxDoctor Payments Data

Bradford Anderson, MD

Pain Medicine · Bakersfield, CANPI 1891806832

Payments from drug & device makers

$765in general payments, 2019–2025

Across 29 payments — averaging $26.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$284
  • Abbott$166
  • Nevro Corp.$71
  • Medtronic$60
  • Electronic Waveform Lab, Inc.$54
  • Johnson & Johnson$42
  • plus $89 from 4 others

What the payments were for

  • Food & beverage$73496%
  • Education$314%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Coloplast7$284
Abbott3$166
Nevro Corp.2$71
Medtronic2$60
Electronic Waveform Lab, Inc.8$54
Johnson & Johnson2$42
Avanir Pharmaceuticals, Inc.2$38
Pfizer1$24
Saol Therapeutics Inc.1$19
Dynasplint Systems Inc.1$8

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$765 in reported general payments places this provider in the 35th percentile of 840 pain medicine providers in California.

See all pain medicine providers in California

Medicare billing

Part B allowed, 2024
$81,750
Medicare patients
180
Services billed
990

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen498$10,791
EliquisApixaban16$8,666
Morphine Sulfate ErMorphine Sulfate109$3,920
Oxycodone Hcl102$3,680
Gabapentin244$2,799
Morphine Sulfate107$2,590
Baclofen137$2,352
Tizanidine Hcl120$1,626
Pregabalin88$1,550
Celecoxib42$1,416
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen70$1,337
Diclofenac Sodium58$1,263
Naloxone Hcl12$910
Alprazolam57$734
Ibuprofen98$563

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$24$8,66616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 840 pain medicine providers in California.

Other pain medicine in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →